Braidwell LP Decreases Stock Position in Harrow, Inc. $HROW

Braidwell LP trimmed its position in shares of Harrow, Inc. (NASDAQ:HROW) by 60.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 342,391 shares of the company’s stock after selling 529,855 shares during the period. Braidwell LP owned approximately 0.92% of Harrow worth $16,496,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. New York State Common Retirement Fund grew its stake in shares of Harrow by 1,944.7% during the third quarter. New York State Common Retirement Fund now owns 213,789 shares of the company’s stock valued at $10,300,000 after acquiring an additional 203,333 shares in the last quarter. Diametric Capital LP purchased a new stake in shares of Harrow during the second quarter worth about $4,748,000. Bank of America Corp DE lifted its stake in shares of Harrow by 266.8% in the second quarter. Bank of America Corp DE now owns 213,448 shares of the company’s stock worth $6,519,000 after acquiring an additional 155,258 shares in the last quarter. Divisadero Street Capital Management LP purchased a new position in Harrow in the second quarter valued at about $4,293,000. Finally, Invesco Ltd. boosted its holdings in Harrow by 967.6% in the second quarter. Invesco Ltd. now owns 150,948 shares of the company’s stock valued at $4,610,000 after purchasing an additional 136,809 shares during the last quarter. Hedge funds and other institutional investors own 72.76% of the company’s stock.

Harrow Stock Down 4.1%

Shares of Harrow stock opened at $34.10 on Friday. The business has a 50-day moving average price of $46.23 and a 200 day moving average price of $43.64. Harrow, Inc. has a fifty-two week low of $20.85 and a fifty-two week high of $54.85. The firm has a market cap of $1.27 billion, a P/E ratio of -200.58 and a beta of 0.05. The company has a quick ratio of 2.06, a current ratio of 2.20 and a debt-to-equity ratio of 4.67.

Analyst Upgrades and Downgrades

HROW has been the subject of a number of recent analyst reports. William Blair restated an “outperform” rating on shares of Harrow in a research note on Tuesday, March 3rd. Cantor Fitzgerald reduced their target price on Harrow from $94.00 to $91.00 and set an “overweight” rating for the company in a research note on Wednesday, March 4th. Zacks Research downgraded shares of Harrow from a “hold” rating to a “strong sell” rating in a research report on Tuesday, March 3rd. HC Wainwright lifted their price target on shares of Harrow from $69.00 to $70.00 and gave the stock a “buy” rating in a research note on Wednesday, March 4th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Harrow in a research note on Thursday, January 22nd. Eight analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to MarketBeat.com, Harrow has a consensus rating of “Moderate Buy” and a consensus price target of $71.14.

Harrow Company Profile

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.